XB-IMG-173261
Xenbase Image ID: 173261
|
|
Figure S3. Chronic small molecule inhibitor treatment results in failure of cardiomyocytes to incorporate into
vertebrate heart while targeted injections to perturb endoderm contractility with arhgef2 enhances ZO-1
polarity. Related to Figure 2 and Figure 5.
(A) 3D projections of Stage 39 embryonic hearts following chronic small molecule inhibitor treatment (stages 20 to
28, ~11 hours) stained for tropomyosin. Arrows show tropomyosin positive cells in the ventral heart forming region
that do not assemble into the developing heart. Scale bar = 100 μm. (B) Transverse sections of stage 28 embryos
stained for tropomyosin (red) and ZO-1 (green) with ZO-1 intensities masked by tropomyosin expression (pseudocolor).
Embryos with endoderm injected with arhgef2-C55R show elevated ZO-1 expression relative to the
rhodamine dextran (RDA) injected control and embryos injected with arhgef2-Y398A. Normalized intensities of
arhgef2-C55R injected embryos are significantly higher than either RDA injected controls of arhgef2-Y398 injected
embryos. Scale bar = 50 μm. ** denotes p < 0.01. Image published in: Jackson TR et al. (2017) Copyright © 2017. Image reproduced with permission of the Publisher, Elsevier B. V. Larger Image Printer Friendly View |